Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tay, M.-H.
Right arrow Articles by Oh, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tay, M.-H.
Right arrow Articles by Oh, W. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:974-978, 2004
© 2004 European Society for Medical Oncology

Original Paper

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate

Received 1 October 2003; revised 30 January 2004; accepted 3 February 2004

Background:

Medical or surgical castration is effective in advanced prostate cancer but with profound side-effects, particularly on sexual function. Effective, less toxic therapies are needed. This study examined whether the addition of finasteride to high-dose bicalutamide enhanced disease control, as measured by additional decreases in serum prostate-specific antigen (PSA).

Patients and methods:

Forty-one patients with advanced prostate cancer received bicalutamide (150 mg/day). Finasteride (5 mg/day) was added at first PSA nadir. Serum PSA was measured every 2 weeks until disease progression. Questionnaires were administered to assess sexual function.

Results:

Median follow-up is 3.9 years. At the first PSA nadir, median decrease in PSA from baseline was 96.5%. Thirty of 41 patients (73%) achieved a second PSA nadir and median decrease of 98.5% from baseline. Median time to each nadir was 3.7 and 5.8 weeks, respectively. Median time to treatment failure was 21.3 months. Toxicities were minor, including gynecomastia. Seventeen of 29 (59%) and 12 of 24 (50%) men had normal sex drive at baseline and at second PSA nadir, respectively. One-third of men had spontaneous erection at both time points.

Conclusion:

Finasteride provides additional intracellular androgen blockade when added to bicalutamide. Duration of control is comparable to castration, with preserved sexual function in some patients.

M.-H. Tay1, D. S. Kaufman2, M. M. Regan3, S. B. Leibowitz1, D. J George1, P. G. Febbo1, J. Manola3, M. R. Smith2, I. D. Kaplan4, P. W. Kantoff1 and W. K. Oh1,*

1 Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2 Department of Medical Oncology, Massachusetts General Hospital, Boston, MA; 3 Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; 4 Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Key words: bicalutamide, finasteride, prostate, potency


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
T. Nishiyama, F. Ishizaki, T. Anraku, H. Shimura, and K. Takahashi
The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate Cancer
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 657 - 660.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.